SCYNEXIS, Inc. (SCYX) Income Statement

NASDAQ: SCYXRevenue, profits, margins and EPS over 10 years.

SCYX 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+449.9%
$20.6M
2025 · hover or tap a bar for each year
2016: $257,000 (0.0%)2017: $257,000 (0.0%)2018: $257,000 (0.0%)2019: $121,000 (−52.9%)2020: $12.1M (+9,858.7%)2021: $13.2M (+9.2%)2022: $5.1M (−61.3%)2023: $140.1M (+2,652.7%)2024: $3.7M (−97.3%)2025: $20.6M (+449.9%)
20162025
Gross profit+449.9%
$20.6M
2025 · hover or tap a bar for each year
2016: $257,000 (0.0%)2017: $257,000 (0.0%)2018: $257,000 (0.0%)2019: $121,000 (−52.9%)2020: −$303,000 (−350.4%)2021: $12.9M2022: $4.5M (−65.3%)2023: $124.5M (+2,690.0%)2024: $3.7M (−97.0%)2025: $20.6M (+449.9%)
20162025
Operating income
−$16.1M
2025 · hover or tap a bar for each year
2016: −$27.8M2017: −$26.3M2018: −$30.0M2019: −$48.9M2020: −$51.1M2021: −$60.8M2022: −$85.8M2023: $72.7M2024: −$37.1M (−151.1%)2025: −$16.1M
20162025
Net income
−$8.6M
2025 · hover or tap a bar for each year
2016: −$30.0M2017: −$25.1M2018: −$12.5M2019: −$53.7M2020: −$55.2M2021: −$32.9M2022: −$62.8M2023: $67.0M2024: −$21.3M (−131.8%)2025: −$8.6M
20162025
EPS (diluted)
$0.54
2025 · hover or tap a bar for each year
2016: −$109.642017: −$60.302018: −$40.192019: −$61.512020: −$22.492021: −$6.732022: −$11.122023: $18.262024: −$2.89 (−115.8%)2025: $0.54
20162025
Net profit margin+526.5 pts
−41.8%
2025 · hover or tap a point for each year
2016: −11,668.9% (+1,024.9 pts)2017: −9,751.0% (+1,917.9 pts)2018: −4,851.4% (+4,899.6 pts)2019: −44,388.4% (−39,537.1 pts)2020: −458.0% (+43,930.5 pts)2021: −249.7% (+208.3 pts)2022: −1,233.7% (−984.0 pts)2023: 47.8% (+1,281.6 pts)2024: −568.3% (−616.1 pts)2025: −41.8% (+526.5 pts)
20162025

SCYX revenue and net income

RevenueNet incomeNet margin (right axis)

Where SCYX's revenue goes

2025
Revenue
$20.6M100.0%
Cost of revenue
$00.0%
Gross profit
$20.6M100.0%
Research & development
−$22.3M−108.2%
Sales, general & admin
−$14.4M−69.9%
Operating income
−$16.1M−78.0%
Interest & other income
$7.5M36.2%
Net income
−$8.6M−41.8%

Each bar shows an amount and its share of revenue. SCYX kept −41.8% of revenue as net income.

SCYX profit margins

GrossOperatingNet

SCYX growth rates

to 2025
1 year3 years5 years10 years
Revenue+449.9%+59.4%+11.3%+55.0%
Gross profit+449.9%+66.5%—+55.0%
Operating income————
Net income————
EPS (diluted)————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

SCYX quarterly EPS vs estimates

Reported EPSAnalyst estimate

SCYNEXIS beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.40).

SCYX income statement

SCYNEXIS, Inc. annual income statement
2025202420232022202120202019201820172016
Revenue$20.6M$3.7M$140.1M$5.1M$13.2M$12.1M$121,000$257,000$257,000$257,000
Cost of revenue$0$0$15.6M$628,000$312,000$303,000$0$0$26.5M$28.0M
Gross profit$20.6M$3.7M$124.5M$4.5M$12.9M−$303,000$121,000$257,000$257,000$257,000
Research & development$22.3M$26.4M$30.9M$27.3M$23.8M$36.5M$38.4M$21.6M$18.3M$20.1M
Sales, general & admin$14.4M$14.5M$33.3M$63.0M$49.9M$14.6M$10.6M$8.7M$8.3M$8.0M
Total operating expenses$36.7M$40.9M$51.8M$90.2M$73.7M$50.8M$49.0M$30.2M$26.6M$28.1M
Operating income−$16.1M−$37.1M$72.7M−$85.8M−$60.8M−$51.1M−$48.9M−$30.0M−$26.3M−$27.8M
Interest income$2.2M$4.3M$3.3M$1.4M$24,000$189,000$805,000$967,000$386,000$185,000
Interest expense$173,000$2.6M$6.1M$6.8M$4.0M$1.2M$2.2M$2.1M$1.9M$451,000
Income before taxes−$8.6M−$21.1M$67.2M−$67.5M−$36.0M−$58.3M−$53.7M−$19.2M−$25.1M−$30.0M
Income taxes—$151,000$138,000−$4.7M−$3.1M−$3.1M$1.5M−$6.7M$1.9M$351,000
Net income−$8.6M−$21.3M$67.0M−$62.8M−$32.9M−$55.2M−$53.7M−$12.5M−$25.1M−$30.0M
EBITDA−$8.1M−$18.6M$70.9M−$60.1M−$32.9M−$55.8M−$51.4M−$17.1M−$23.2M−$29.5M
EPS (diluted)$0.54−$2.89$18.26−$11.12−$6.73−$22.49−$61.51−$40.19−$60.30−$109.64
Gross margin100.0%100.0%88.9%87.7%97.6%−2.5%100.0%100.0%100.0%100.0%
Operating margin−78.0%−990.8%51.9%−1,684.5%−462.2%−424.5%−40,430.6%−11,666.5%−10,241.2%−10,823.7%
Net margin−41.8%−568.3%47.8%−1,233.7%−249.7%−458.0%−44,388.4%−4,851.4%−9,751.0%−11,668.9%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SCYX's financial statements (latest annual report filed March 4, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

SCYX financial results

In fiscal year 2025 (ended December 31, 2025), SCYNEXIS reported revenue of $20.6 million, up 449.9% from the year before. It had a net loss of $8.6 million, a net profit margin of −41.8%. Diluted earnings per share came to $0.54. Over five years revenue grew at an average rate of 11.3% a year.

See the SCYX stock overview for the latest quote and news, or the SCYX chart for price history and technical indicators.

SCYX income statement FAQ

What is SCYNEXIS's annual revenue?

SCYNEXIS reported total revenue of $20.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 449.9% from $3.7 million the previous year.

Is SCYNEXIS profitable?

No. SCYNEXIS reported a net loss of $8.6 million in fiscal 2025, a net profit margin of −41.8%; its operating margin was −78.0%.

What is SCYNEXIS's gross margin?

SCYNEXIS's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, SCYNEXIS kept $100 after the direct cost of its products and services.

How much does SCYNEXIS spend on research and development?

SCYNEXIS spent $22.3 million on research and development in fiscal 2025, 108.2% of revenue.

How fast is SCYNEXIS growing?

Revenue grew 11.3% a year on average over the last five fiscal years, from $12.1 million to $20.6 million.

What are SCYNEXIS's earnings per share?

SCYNEXIS earned $0.54 per diluted share in fiscal 2025, compared with $-2.89 a year earlier.

When will SCYNEXIS report its next earnings?

SCYNEXIS is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.

When does SCYNEXIS's fiscal year end?

SCYNEXIS's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 4, 2026.

Drug Manufacturers - Specialty & Generic income statements